Abstract
Matrix metalloproteinases (MMPs), are proteinases that participate in extracellular matrix remodelling and degradation. Under normal physiological conditions, the activities of MMPs are regulated at the level of transcription, of activation of the pro-MMP precursor zymogens and of inhibition by endogenous inhibitors (tissue inhibitors of metalloproteinases; TIMPs). Alteration in the regulation of MMP activity is implicated in atherosclerotic plaque development, coronary artery disease and heart failure. The pathological effects of MMPs and TIMPs in cardiovascular diseases involve vascular remodelling, atherosclerotic plaque instability and left ventricular remodelling after myocardial infarction. Since excessive tissue remodelling and increased matrix metalloproteinase activity have been demonstrated during atherosclerotic lesion progression, MMPs represent a potential target for therapeutic intervention aimed at modification of vascular pathology by restoring the physiological balance between MMPs and TIMPs. This review discusses pharmacological approaches to MMP inhibition.
Keywords: Metalloproteinase, tissue inhibitors of metalloproteinases, atherosclerosis, extracellular matrix, degradation, endogenous inhibitors, atherosclerotic plaque, coronary artery disease, vascular remodelling, heart failure, myocardial infarction, vascular pathology, pharmacological approaches to MMP inhibition
Current Topics in Medicinal Chemistry
Title:Novel Therapeutic Approaches Targeting Matrix Metalloproteinases in Cardiovascular Disease
Volume: 12 Issue: 10
Author(s): Alexandros Briasoulis, Dimitris Tousoulis, Nikolaos Papageorgiou, Anna-Maria Kampoli, Emmanuel Androulakis, Charalambos Antoniades, Eleftherios Tsiamis, George Latsios and Christodoulos Stefanadis
Affiliation:
Keywords: Metalloproteinase, tissue inhibitors of metalloproteinases, atherosclerosis, extracellular matrix, degradation, endogenous inhibitors, atherosclerotic plaque, coronary artery disease, vascular remodelling, heart failure, myocardial infarction, vascular pathology, pharmacological approaches to MMP inhibition
Abstract: Matrix metalloproteinases (MMPs), are proteinases that participate in extracellular matrix remodelling and degradation. Under normal physiological conditions, the activities of MMPs are regulated at the level of transcription, of activation of the pro-MMP precursor zymogens and of inhibition by endogenous inhibitors (tissue inhibitors of metalloproteinases; TIMPs). Alteration in the regulation of MMP activity is implicated in atherosclerotic plaque development, coronary artery disease and heart failure. The pathological effects of MMPs and TIMPs in cardiovascular diseases involve vascular remodelling, atherosclerotic plaque instability and left ventricular remodelling after myocardial infarction. Since excessive tissue remodelling and increased matrix metalloproteinase activity have been demonstrated during atherosclerotic lesion progression, MMPs represent a potential target for therapeutic intervention aimed at modification of vascular pathology by restoring the physiological balance between MMPs and TIMPs. This review discusses pharmacological approaches to MMP inhibition.
Export Options
About this article
Cite this article as:
Briasoulis Alexandros, Tousoulis Dimitris, Papageorgiou Nikolaos, Kampoli Anna-Maria, Androulakis Emmanuel, Antoniades Charalambos, Tsiamis Eleftherios, Latsios George and Stefanadis Christodoulos, Novel Therapeutic Approaches Targeting Matrix Metalloproteinases in Cardiovascular Disease, Current Topics in Medicinal Chemistry 2012; 12 (10) . https://dx.doi.org/10.2174/1568026611208011214
DOI https://dx.doi.org/10.2174/1568026611208011214 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Increased Risk of Dementia in Patients with Non-Apnea Sleep Disorder
Current Alzheimer Research Sigma-1 Receptors: Potential Targets for the Treatment of Substance Abuse
Current Pharmaceutical Design The Cytoprotective and Anti-cancer Potential of Bisbenzylisoquinoline Alkaloids from <I>Nelumbo nucifera</I>
Current Topics in Medicinal Chemistry Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
Current Pharmaceutical Design Induced Pluripotent Stem Cells (iPSCs) Derived from Different Cell Sources and their Potential for Regenerative and Personalized Medicine
Current Molecular Medicine Riboregulators and Metabolic Disorders: Getting Closer Towards Understanding the Pathogenesis of Diabetes Mellitus?
Current Molecular Medicine Statins May Prevent Atherosclerotic Disease in OSA Patients without Co-Morbidities?
Current Vascular Pharmacology Subclinical Thyroid Dysfunction and Cardiovascular Outcomes among Prospective Cohort Studies
Endocrine, Metabolic & Immune Disorders - Drug Targets The Effect of a Four-Week Balance Training Program on Anticipatory Postural Adjustments in Older Adults: A Pilot Feasibility Study
Current Aging Science Blockade of the Renin-Angiotensin-Aldosterone System: Effects on Hypertensive Target Organ Damage
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting of Low-Molecular Weight Drugs to Mammalian Mitochondria
Drug Design Reviews - Online (Discontinued) Current Management of Traumatic Rupture of the Descending Thoracic Aorta
Current Cardiology Reviews Detection of Predictive Markers for Therapeutic Stratification of Salivary Glands Tumors
Current Drug Targets Chromogranin A in Tumors: More Than a Marker for Diagnosis and Prognosis
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Role of Polyphenol in Regulating Oxidative Stress, Inflammation, Fibrosis, and Apoptosis in Diabetic Nephropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Revascularization vs. Optimal Medical Therapy in Women with NSTE-ACS
Current Pharmaceutical Design Cardiovascular Disease Burden and Risk Factors Before and After Kidney Transplant
Cardiovascular & Hematological Disorders-Drug Targets Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer’s Disease: A Phase 2, Open-Label Extension Study
Current Alzheimer Research Lipid Management and Peripheral Arterial Disease
Current Drug Targets Hypertension and Cardiac Arrhythmias
Current Pharmaceutical Design